GlassScriptPhysician profile
Lidia M Berrone
NPI 1467451930
$18,723.08
in general payments reported to CMS, 2019-2025
26 companies · $3,440 in 2025
The $3,440 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,821 · 2022: $3,471 · 2023: $4,506 · 2024: $3,485 · 2025: $3,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $25.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,406.52 |
| Education | $25.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,873.79 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $3,522.04 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,330.11 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $1,685.24 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $1,646.02 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $1,043.32 | 2023-2025 | Auvelity, Symbravo |
| Sunovion Pharmaceuticals INC. | $813.01 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $725.70 | 2024-2025 | Cobenfy, Coumadin |
| Vanda Pharmaceuticals INC. | $660.92 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $529.68 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $488.99 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $328.96 | 2021-2025 | Ingrezza |
| Gilead Sciences, INC. | $220.97 | 2021-2023 | Descovy |
| Braeburn INC. | $145.73 | 2023 | Brixadi |
| Validus Pharmaceuticals LLC | $135.15 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $118.90 | 2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $103.26 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $94.89 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $86.48 | 2021-2025 | Secuado, Xelstrym |
| Indivior INC. | $39.11 | 2022 | |
| Corium, LLC | $31.25 | 2023 | Azstarys |
| Bausch Health US, LLC | $25.51 | 2022 | |
| Avanir Pharmaceuticals, INC. | $24.11 | 2022 | |
| Boston Scientific Corporation | $19.24 | 2021 | |
| Almatica Pharma LLC | $17.92 | 2022 | |
| Supernus Pharmaceuticals, INC. | $12.78 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lidia Berrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.